Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808060) titled 'A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Obesity
Overweight
Intervention:
Drug: Eloralintide
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 34
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07808060
Published by HT Digital...